Biogen's experimental drug diranersen slowed cognitive decline by 26% on one test in one low-dose subset of a roughly 400-person Phase 2 trial, results presented Tuesday at the Alzheimer's Association International Conference in London showed — a number now traveling far faster than the caveat attached to it [1]. The same trial missed its planned goal of proving that higher doses work better, because the lowest dose, given every six months, produced the strongest effect. That inverted dose-response is the fact that separates a genuine early signal from the breakthrough-or-cure headline circulating on biotech and Alzheimer's feeds, where the single 26% figure and the drug's ability to lower a toxic brain protein have been compressed into a claim of arrival.

Diranersen attacks Alzheimer's from a different direction than today's approved medicines. Lecanemab and donanemab clear buildup of the better-known amyloid protein and modestly slow decline [1]. Diranersen instead targets tau, the other half of what AP calls a "toxic duo" fueling the disease, and prior attempts to drug tau have failed [1]. It is an antisense oligonucleotide — it does not attack existing tau tangles but instructs a tau-producing gene to make less of the protein in the first place. "If you lower tau production, you are lowering the amount of the abnormal tau that needs to be cleared by the microglia, by the clearance mechanism in the brain," said Dr. Cath Mummery of University College London, who led the study. "And so you are enabling the normal clearance mechanism to have more capacity to clear the tau" [1].

The delivery is also unusual. Anti-amyloid drugs are given through the bloodstream by infusion or injection; diranersen is injected into the fluid surrounding the spinal cord, a straighter path to the brain [1]. That twice-a-year spinal shot is part of what makes the drug easy to romanticize online — but it is also the source of side effects the celebratory frame drops. Mummery reported injection-site pain and a temporary state of confusion that could appear a few days after the shot and last about a week [1]. There were no signs of the brain inflammation that can afflict recipients of anti-amyloid drugs, a meaningful safety contrast, but "no inflammation" is not the same as "no cost."

The 26% number needs its full sentence to be honest. Five of six brain tests showed diranersen recipients' memory and other cognitive abilities still worsened — only more slowly than those given dummy shots, Mummery said [1]. In one test at the lowest dose, that slower worsening translated to a 26% reduction in cognitive decline, which Mummery called "approximately the same" change seen in earlier tests of amyloid drugs [1]. Read carefully, that is a relative slowing of decline in one subset on one scale, not a 26% recovery of memory and not proof that every dose helps. Participants declined. The comparison it earns is to existing amyloid therapy's modest effect, not to a cure — and the trial did not establish the dose that a doctor would prescribe.

Independent researchers at the conference drew the line the online enthusiasm erases. "This is really quite promising if it were to hold up" in next-step testing, said Jessica Langbaum of the Banner Alzheimer's Institute in Phoenix, who was not involved in the study [1]. Her whole point rests on the conditional. "This is early days," cautioned Dr. Reisa Sperling of Mass General Brigham, also unaffiliated with the work, before adding the reason the result still matters: "I think it will reinvigorate interest and investment in lots of tau mechanisms, and the field needs that" [1]. The value scientists see is directional — evidence that lowering tau production can move a clinical needle at all — not a finished treatment.

Biogen is planning a larger study to try to prove the benefit, and that confirmatory trial is where the missing consequence lives [1]. Phase 3 has to reproduce a clinical benefit, settle on a dose that the current data actively muddied, characterize the confusion side effect over longer follow-up, and show how the spinal shot stacks up against amyloid drugs already on the market. None of that is done. Until it is, the 26% figure describes one arm of one mid-stage trial, not an option any patient can choose.

The result also arrives amid a broader turn toward tau. The University of California, San Francisco last week opened a first-of-its-kind, NIH-funded study called the Alzheimer's Tau Platform, which will test experimental anti-tau therapies against and alongside today's amyloid treatments, starting with a vaccine called AADvac1, said UCSF's Dr. Adam Boxer [1]. Researchers at the same London meeting also reported that an experimental cholesterol drug, obicetrapib, might lower Alzheimer's-related protein buildup in people carrying the APOE4 genetic risk variant, and Denali Therapeutics is pursuing a "transport vehicle" that its CEO Ryan Watts describes as "hitching a ride" with iron to carry tau and amyloid drugs across the blood-brain barrier [1]. Alzheimer's affects more than 7 million Americans and tens of millions worldwide [1]. That scale is exactly why the honest version of Tuesday's news — a promising early signal that missed its own primary goal — deserves to travel as far as the shorthand that dropped the caveat.

-- Kenji Nakamura, San Francisco